Scientific Blogs

The latest developments of Medis QFR®

December 2022 edition

Written by Prof. Hans Reiber on December 8, 2022

Given the regular posts of peer-reviewed scientific publications on the developments of Medis QFR ®, it is clear that this angio-based solution for coronary physiology is extensively used in clinical research and practice. We would like to share these publications with you so that you remain up to date about the research that is ongoing worldwide with this innovative solution, whereby each time new clinical applications are being tested, validated and tried out in particular populations. With its non-invasive nature, readily available, and broad applicability, we anticipate a significant growth in its usage, supported by our constant quest for further automation.

In this new Medis QFR® blog, we are proud to share four publications on the latest developments of Medis QFR with you.

Predictors of vessel quantitative flow ratio loss in patients with severely calcified lesions after rotational atherectomy

Dr. Y Zhou and colleagues from Anhui Medical University and Nanjing Medical University in China under the supervision of Dr. Hu published this paper in the Cardiology Journal. This is a retrospective study of 111 patients with moderately to severely calcified lesions (MSCLs). Drug-eluting stents were implanted after rotational atherectomy and the mean follow-up was 382 days. The patients were divided into high QFR loss (>0.01) and low QFR loss (<0.01). The cut-off value of the final Burr-Vessel ratio for QFR loss prediction was 0.50. The authors concluded that an increased burr-to-vessel ratio can prevent QFR loss in patients with MSCLs after atherectomy, an effect that might be closely associated with a low target-vessel-failure incidence.

For further read:

Editorial Comment on the two-year outcome of the FAVOR III China Trial

Dr. Morton Kern and Dr. Arnold H Seto wrote a very important Editorial Comment on this trial. They acknowledge that the FAVOR III China trial is the largest randomized coronary physiology outcome study to date. They summarize that the QFR®, like FFR, is not affected by DM. QFR-guided intervention, like FFR-guided intervention, is superior to angiographically guided intervention in terms of MACE. Also, very interesting to note is that the annual number of publications of the QFR continues to increase sharply and has surpassed the iFR publications!

For further read:

Interested in the developments of Medis QFR ®?

Easily request a demo of our innovative software solution

Physiologic distribution and local severity of CAD; Editorial comments on the paper by N. Dai et al.

Dr. J.M. Lee and Dr. S.H. Lee wrote a very interesting Editorial Comment in JACC Interventions on the paper by Dai N. et al. They support the approach that this 2-dimensional characterization of disease patterns would provide additional data to better select PCI can candidates, improve immediate functional outcomes of the procedure, and enhance overall patient clinical outcome after PCI.

For further read:

Relation between coronary plaque composition assessed by intravascular ultrasound virtual histology and myocardial ischemia assessed by Quantitative Flow Ratio

Dr. J.M. Smit and many co-authors under the supervision of J.J. Bax of the Leiden University Medical Center in the Netherlands published this work in the Americal Journal of Cardiology. This was a retrospective analysis of 103 patients who were referred to diagnostic invasive coronary angiography. The objective was to clarify the relation between coronary plaque composition by IVUS VH and myocardial ischemia (QFR<0.8), based on the angio-based FFR approach by Medis. The authors concluded that the noncalcified plaque area was significantly higher in hemodynamically significant coronary lesions than in nonsignificant lesions.

For further read:

Share this article on:


Interested in the developments of Medis QFR?

Easily request a demo of our innovative software solution

Sign up for our newsletter

Subscribe now to find out more about our solutions, latest publications and future releases.

By providing your information and continuing, you agree to Medis’ Terms of Use and Privacy Policy *